Medicines for Malaria Venture (MMV) is a Swiss-based not-for-profit organization working through a product development partnership model to deliver a portfolio of accessible medicines with the power to treat, prevent and eliminate malaria.
Born in 1999, out of a need for greater health equity, we close critical gaps in research, development and access – working “end-to-end” to expand the use of existing antimalarials and innovate new compounds to protect public health, especially pregnant women and children, who are the groups most vulnerable to malaria infection and death.
As of 2024, MMV-supported products have effectively treated an estimated 711 million people and 1.3 billion courses of malaria preventive medicine have been received by children.
